P/E ratio for Exact Sciences (EXAS)
P/E ratio as of April 2024 (TTM): -37.1
According to Exact Sciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -37.0772. At the end of 2022 the company had a P/E ratio of -14.0.
P/E ratio history for Exact Sciences from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -14.0 | -37.82% |
| 2021 | -22.5 | -6.62% |
| 2020 | -24.1 | -81.51% |
| 2019 | -130 | 197.25% |
| 2018 | -43.8 | -16.6% |
| 2017 | -52.5 | 548.88% |
| 2016 | -8.10 | 49.13% |
| 2015 | -5.43 | -75.46% |
| 2014 | -22.1 | 29.95% |
| 2013 | -17.0 | 41.51% |
| 2012 | -12.0 | -19.97% |
| 2011 | -15.0 | -29.59% |
| 2010 | -21.4 | 82.7% |
| 2009 | -11.7 | 638.29% |
| 2008 | -1.58 | -78.36% |
| 2007 | -7.32 | 26.71% |
| 2006 | -5.78 | 43.73% |
| 2005 | -4.02 | -23.41% |
| 2004 | -5.25 | -22.23% |
| 2003 | -6.75 | 0.92% |
| 2002 | -6.69 | -5.52% |
| 2001 | -7.08 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 15.5 | -141.86% | 🇫🇷 France |
 Veracyte VCYT | -48.7 | 31.35% | 🇺🇸 USA |
 Antares Pharma ATRS | 16.4 | -144.34% | 🇺🇸 USA |
 Myriad Genetics MYGN | -5.91 | -84.05% | 🇺🇸 USA |
 Biocept
BIOC | -0.0085 | -99.98% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.